Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

PartnershipUpdated on 30 April 2026

AT-31 BIO: Leading the immunology shift with next-gen immunosuppressive breakthroughs for complex disorders.

Do Youn Chun

Chief Technical Officer at AT-31 BIO Inc.

Daegu, South Korea

About

AT-31 BIO Lab has developed GJK-012, a novel immunomodulatory substance for use in innovative eye drops to treat dry eye syndrome in patients with Sjögren's syndrome. The global dry eye market exceeds $6 billion annually, with a significant unmet treatment need for Sjögren's patients.

We are seeking partners for collaborative new drug development using GJK-012. If your organization is interested in co-development, clinical research, or licensing opportunities with this water-soluble immunosuppressant, please contact us.

 Investment partners

We are seeking a capital partnership to accelerate our pipeline. The intended use of funds includes advancing GJK-012 through clinical trials, expanding our R&D team, and supporting the regulatory submission process. This targeted investment will help us deliver innovative eye care solutions to a substantial, underserved patient population.

 New drug co-developers

We are open to joint R&D collaboration to leverage complementary expertise

 Big Pharma (M&A)

We wish to discuss out-licensing our lead compound. GJK-012 is protected by a recently filed international patent application (patent-pending), ensuring exclusive rights and commercial advantage for future partners.

Similar opportunities